News|Articles|September 25, 2023
Changing regulatory environment for nitrosamine impurities
Author(s)SGS Health Science
This SGS Health Science whitepaper uncovers the changing regulatory environment, and the challenges posed by the detection of nitrosamine impurities in drug products.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
Next-Generation Modalities Drive New Antibody Discovery
5